{"nctId":"NCT02248636","briefTitle":"Cholinesterase Inhibitor Discontinuation","startDateStruct":{"date":"2015-01-22","type":"ACTUAL"},"conditions":["Dementia"],"count":72,"armGroups":[{"label":"Real discontinuation","type":"EXPERIMENTAL","interventionNames":["Drug: Cholinesterase inhibitor"]},{"label":"Sham discontinuation","type":"SHAM_COMPARATOR","interventionNames":["Drug: Sham discontinuation"]}],"interventions":[{"name":"Cholinesterase inhibitor","otherNames":[]},{"name":"Sham discontinuation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females ages 60 and older.\n* Taking stable dose of donepezil 10mg or greater per day, or galantamine 8mg or greater per day, for at least 1 year.\n* Presence of a primary caregiver who can assume responsibility for medication compliance, OR residence in a nursing home with a staff member who can provide information.\n* Primary care visit within last 12 months.\n* Willing to have the CI medication discontinued.\n\nExclusion Criteria:\n\n* Terminal medical condition for which life expectancy would be less than 6 months.\n* Parkinson's Disease\n* Presence of any uncontrolled systemic illness that would interfere with participation in the study.\n* Unstable medical condition.\n* Receiving services from hospice.\n* Current prescription with more than one CI\n* Receiving medication in an investigational drug study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"60 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Successful Completion","description":"Participants can return to their pre-study dose of medication at any time. If they complete 6 weeks of either real discontinuation or sham discontinuation, they are considered to have successfully completed treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Caregiver Burden","description":"The Zarit Caregiver Burden Interview contains 22 items, each on a 5-point scale, for a maximum score of 110. The minimum score is 0. A higher score indicates worse subjective burden.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.58","spread":"11.13"},{"groupId":"OG001","value":"1.66","spread":"17.56"}]}]}]},{"type":"SECONDARY","title":"Veteran Cognition","description":"Six-Item Screener is a telephone-based assessment of cognitive status. The score ranges from 0 to 6. A higher score indicates better cognition.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"2.13"},{"groupId":"OG001","value":"0.13","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"Veteran Functioning","description":"The Alzheimer's Disease Cooperative Study ADL Scale (ADCS-ADL) is a 23-item scale divided into activities of daily living and independent activities of daily living. Scores range from 0-78. A lower score indicates worse functional ability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"11.87"},{"groupId":"OG001","value":"-0.59","spread":"6.72"}]}]}]},{"type":"SECONDARY","title":"Behavioral Symptoms","description":"The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) is a 25-item instrument. Scores range from 0-75, with a higher number indicating worse behavioral symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.63","spread":"6.26"},{"groupId":"OG001","value":"-1.23","spread":"3.79"}]}]}]},{"type":"SECONDARY","title":"Post-study Treatment Choice","description":"Veteran and caregiver decision to continue, or to have restarted, the pre-study medication at 12 weeks. The participants were unblinded at 6 weeks, and were requested to make their own decision about restarting.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Behavior"]}}}